-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AMB-051 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMB-051 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMB-051 in Non-Small Cell Lung Cancer Drug Details: AMB-051 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MHB-088C in Esophageal Squamous Cell Carcinoma (ESCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Esophageal Squamous Cell Carcinoma (ESCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MHB-088C in Esophageal Squamous Cell Carcinoma (ESCC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mecbotamab Vedotin in Castration-Resistant Prostate Cancer (CRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mecbotamab Vedotin in Castration-Resistant Prostate Cancer (CRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mecbotamab Vedotin in Castration-Resistant Prostate Cancer (CRPC) Drug Details:...
-
Product Insights
Tenosynovial Giant Cell Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Tenosynovial Giant Cell Tumor - Drugs In Development, 2023’, provides an overview of the Tenosynovial Giant Cell Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tenosynovial Giant Cell Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Malignant Fibrous Histiocytoma of Soft Tissue – Drugs In Development, 2023
Global Markets Direct’s, ‘Malignant Fibrous Histiocytoma of Soft Tissue - Drugs In Development, 2023’, provides an overview of the Malignant Fibrous Histiocytoma of Soft Tissue pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malignant Fibrous Histiocytoma of Soft Tissue, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Malignant Fibrous Histiocytoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Malignant Fibrous Histiocytoma - Drugs In Development, 2023’, provides an overview of the Malignant Fibrous Histiocytoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malignant Fibrous Histiocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Polycystic Kidney Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Polycystic Kidney Disease - Drugs In Development, 2023’, provides an overview of the Polycystic Kidney Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Macular Edema – Drugs In Development, 2023
Global Markets Direct’s, ‘Macular Edema - Drugs In Development, 2023’, provides an overview of the Macular Edema pipeline landscape. The report provides comprehensive information on the therapeutics under development for Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...